Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)

China flag China · Delayed Price · Currency is CNY
55.77
-0.43 (-0.77%)
At close: Apr 28, 2026
-1.47%
Market Cap 25.94B
Revenue (ttm) 801.14M
Net Income (ttm) -764.05M
Shares Out 465.17M
EPS (ttm) -1.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,038,308
Average Volume 4,043,718
Open 56.00
Previous Close 56.20
Day's Range 55.52 - 57.69
52-Week Range 46.66 - 86.18
Beta -0.02
RSI 49.26
Earnings Date Mar 31, 2026

About SHA:688192

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of cancer and immunological diseases. Its assets include the ZEGFROVY, for the treatment of solid tumors; Golidocitinib to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. The company was founded in 2017 and is based in Shan... [Read more]

Sector Healthcare
Founded 2017
Employees 1,009
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688192
Full Company Profile

Financial Performance

In 2025, SHA:688192's revenue was 801.14 million, an increase of 122.60% compared to the previous year's 359.90 million. Losses were -764.05 million, -9.68% less than in 2024.

Financial Statements

News

There is no news available yet.